In a patient with epilepsy taking levetiracetam 750 mg orally every 12 hours who has a trough serum concentration of 2.5 µg/mL (below the tentative therapeutic range of 4–46 µg/mL), how should the low level be managed and the dose adjusted?

Management of Low Levetiracetam Level in Intractable Epilepsy

In this patient with intractable epilepsy on levetiracetam 750 mg twice daily showing a subtherapeutic trough level of 2.5 µg/mL, the dose should be increased, but clinical seizure control takes absolute priority over achieving any specific serum concentration, as the therapeutic range for levetiracetam remains poorly validated and the concentration-response relationship is weak.

Understanding Levetiracetam Therapeutic Monitoring

The tentative reference range of 4-46 µg/mL (or 6-46 µg/mL in some sources) has not been validated by adequate controlled trials 1. The relationship between serum concentrations and clinical effect remains poorly defined 1. This is a critical distinction from traditional antiepileptic drugs where therapeutic ranges are more established.

Key Pharmacokinetic Considerations

• Linear pharmacokinetics: Levetiracetam exhibits dose-proportional kinetics from 500-5000 mg 1
• Renal elimination: 66% excreted unchanged in urine; clearance directly correlates with creatinine clearance 1
• Half-life: Approximately 6-8 hours in adults 1
• Steady state: Achieved after 2 days of twice-daily dosing 1
• Minimal protein binding: <10% bound, reducing drug interaction potential 1

Factors Contributing to Low Levels

Before adjusting the dose, evaluate these specific factors:

1. Medication Adherence

The most common cause of low levels. Direct questioning about missed doses is essential.

2. Renal Function

Check serum creatinine and calculate creatinine clearance. Normal renal function should yield predictable levels 1.

3. Drug Interactions

• Enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin, phenobarbital) can increase levetiracetam clearance by approximately 22% 1, 2
• Carbamazepine specifically reduces levetiracetam concentration-to-dose ratio by 30-46% 2
• Critical pitfall: Clinicians often fail to recognize this interaction and prescribe similar doses regardless of co-medication 2

4. Timing of Sample

Confirm this was a true trough level (immediately before next dose). Levetiracetam reaches peak concentration in approximately 1 hour 1.

5. Body Weight

Clearance is allometrically related to body weight 3. Larger patients may require higher doses.

Dose Adjustment Strategy

For Adults with Partial Onset Seizures (per FDA labeling):

Initial approach 1:

• Current dose: 1500 mg/day (750 mg BID)
• Recommended increase: Add 1000 mg/day increments every 2 weeks
• Next step: Increase to 2500 mg/day (1250 mg BID) or 3000 mg/day (1500 mg BID)
• Maximum recommended dose: 3000 mg/day
• Doses >3000 mg/day have been used in open-label studies but show no evidence of additional benefit 1

Specific Dosing Algorithm:

1. If seizures are controlled at current level: Consider maintaining current dose despite low level, as clinical response supersedes laboratory values

2. If seizures are not controlled:

   • Increase to 1000 mg BID (2000 mg/day total)
   • Reassess clinically in 2 weeks
   • If inadequate response, increase to 1500 mg BID (3000 mg/day total)
   • Recheck level at steady state (after 2 days at new dose) if needed for compliance assessment

3. If on enzyme-inducing AEDs (especially carbamazepine):

   • Anticipate need for higher doses (potentially 30-46% higher) 2
   • Consider more aggressive dose escalation
   • Target clinical seizure control rather than specific serum levels

Special Considerations

Renal Impairment

If creatinine clearance is reduced, dose adjustments are mandatory 1:

• CrCl 50-80 mL/min: 500-1000 mg every 12 hours
• CrCl 30-50 mL/min: 250-750 mg every 12 hours
• CrCl <30 mL/min: 250-500 mg every 12 hours
• ESRD on dialysis: 500-1000 mg once daily with supplemental 250-500 mg after dialysis

Age-Related Factors

Elderly patients show 38% decreased clearance and 2.5-hour longer half-life due to reduced renal function 1, 4. Age is a significant predictor of target concentration attainment 4.

Pharmacokinetic Variability

Recent evidence demonstrates extensive pharmacokinetic variability in real-world practice 2. The coefficient of variation for trough concentrations can exceed 64-69% 4, meaning identical doses produce widely different levels between patients.

Clinical Monitoring Approach

Do not rely solely on serum levels for dose adjustment. The evidence-based approach prioritizes:

1. Seizure frequency and severity (primary outcome)
2. Adverse effects (neuropsychiatric symptoms most common, especially irritability and behavioral changes) 5
3. Serum levels (tertiary consideration for compliance assessment and extreme values)

When to Recheck Levels:

• After dose changes (wait ≥2 days for steady state)
• If breakthrough seizures occur
• To assess compliance
• If adverse effects develop
• If renal function changes

Common Pitfalls to Avoid

1. Over-reliance on therapeutic range: The 4-46 µg/mL range is tentative and unvalidated 1. Many patients achieve seizure control below this range.

2. Ignoring enzyme-inducing AED interactions: Failure to account for carbamazepine, phenytoin, or phenobarbital co-administration leads to systematic underdosing 2.

3. Not assessing renal function: Levetiracetam clearance is directly proportional to creatinine clearance 1, 6.

4. Premature dose escalation: If seizures are controlled, low levels may be adequate for that individual patient.

5. Excessive dose escalation: Doses >3000 mg/day show no additional benefit 1 and increase adverse effect risk.

Evidence Quality Note

The guidelines provided [7-7-7] address levetiracetam use in CAR T-cell therapy complications, not primary epilepsy management, and are therefore not directly applicable to this clinical scenario. The most relevant evidence comes from the FDA drug label [1-1] and recent pharmacokinetic studies [8-9,10] demonstrating significant inter-individual variability and the limited utility of routine therapeutic drug monitoring for levetiracetam.